Survivin gene therapy attenuates left ventricular systolic dysfunction in doxorubicin cardiomyopathy by reducing apoptosis and fibrosis

Cardiovascular Research

Volumn 101, Issue 3, 2014, Pages 423-433

  Lee, Paul J H ^a   Rudenko, Dmitriy ^a   Kuliszewski, Michael A ^a   Liao, Christine ^a   Kabir, M Golam ^a   Connelly, Kim A ^a   Leong Poi, Howard ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Apoptosis; Cardiomyopathy; Gene therapy; Heart failure; Survivin

Indexed keywords

APOPTOSIS; CARDIOMYOPATHY; GENE THERAPY; HEART FAILURE; SURVIVIN;

ANIMALS; APOPTOSIS; CARDIOMYOPATHIES; CELL LINE; DOXORUBICIN; FIBROSIS; GENETIC THERAPY; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MYOCARDIUM; RATS; REPRESSOR PROTEINS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84894593113     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu001     Document Type: Article

References (39)

1. Gheorghiade M, Vaduganathan M, FonarowGC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J AmColl Cardiol 2012; pii:S0735-1097(12)05296-5. (Epub ahead of print).
2. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012;33:1750-1757.
3. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011;378:704-712.
4. Tijsen AJ, Pinto YM, Creemers EE. Non-cardiomyocyte microRNAs in heart failure. Cardiovasc Res 2012;93:573-582.
5. Narula J, Haider N, Arbustini E, Chandrashekhar Y. Mechanisms of disease: apoptosis in heart failure: seeing hope in death. Nat Clin Pract Cardiovasc Med 2006;3:681-688.
6. Dorn GW II. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res 2009;81:465-473.
7. Abbate A, Biondi-Zoccai GG, Bussani R, Dobrina A, Camilot D, Feroce F et al. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol 2003;41:753-760.
8. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI. Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 2004;110:1083-1090.
9. Soga M, Kamal FA, Watanabe K, Ma M, Palaniyandi S, Prakash P et al. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol 2006;110:378-385.
10. Haunstetter A, Izumo S. Toward antiapoptosis as a new treatment modality. Circ Res 2000;86:371-376.
11. Tilemann L, Ishikawa K, Weber T, Hajjar RJ. Gene therapy for heart failure. Circ Res 2012; 110:777-793.
12. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
13. Levkau B, Schafers M, Wohlschlaeger J, von Wnuck Lipinski K, Keul P, Hermann S et al. Survivin determines cardiac function by controlling total cardiomyocyte number. Circulation 2008;117:1583-1593.
14. Abbate A, Scarpa S, Santini D, Palleiro J, Vasaturo F, Miller J et al. Myocardial expression of survivin, an apoptosis inhibitor, in aging and heart failure. An experimental study in the spontaneously hypertensive rat. Int J Cardiol 2006;111:371-376.
15. Khan S, Jutzy JM, Aspe JR, McGregorDW, NeidighJW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis 2011;16:1-12.
16. Leong-Poi H, KuliszewskiMA, LekasM, Sibbald M, Teichert-Kuliszewska K, Klibanov AL et al. Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. CircRes 2007;101:295-303.
17. Smith AH, Kuliszewski MA, Liao C, Rudenko D, Stewart DJ, Leong-Poi H. Sustained improvement in perfusion and flow reserve after temporally separated delivery of vascular endothelial growth factor and angiopoietin-1 plasmid deoxyribonucleic acid. J Am Coll Cardiol 2012;59:1320-1328.
18. Kuliszewski MA, Kobulnik J, Lindner JR, Stewart DJ, Leong-Poi H. Vascular gene transfer of SDF-1 promotes endothelial progenitor cell engraftment and enhances angiogenesis in ischemic muscle. Mol Ther 2011;19:895-902.
19. Kobulnik J, Kuliszewski MA, Stewart DJ, Lindner JR, Leong-Poi H. Comparison of gene delivery techniques for therapeutic angiogenesis ultrasound-mediated destruction of carrier microbubbles versus direct intramuscular injection. J Am Coll Cardiol 2009;54: 1735-1742.
20. Fujii H, LiSH, Wu J, MiyagiY, Yau TM, RakowskiHet al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J 2011;32:2075-2084.
21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PAet al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society ofCardiology. J AmSoc Echocardiog 2005;18:1440-1463.
22. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, Cox AJ et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009;2:129-137.
23. Wencker D, Chandra M, Nguyen K, MiaoW, Garantziotis S, Factor SM et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003;111:1497-1504.
24. Lladser A, Sanhueza C, Kiessling R, Quest AF. Is survivin the potential Achilles' heel of cancer? Adv Cancer Res 2011;111:1-37.
25. Santini D, Abbate A, Scarpa S, Vasaturo F, Biondi-Zoccai GG, Bussani R et al. Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction. J Clin Pathol 2004;57:1321-1324.
26. Wohlschlaeger J, Meier B, Schmitz KJ, Takeda A, Takeda N, VahlhausCet al. Cardiomyocyte survivin protein expression is associated with cell size andDNAcontent in the failing human heart and is reversibly regulated after ventricular unloading. J Heart Lung Transplant 2010;29:1286-1292.
27. Kass DA, Maughan WL. From 'Emax' to pressure-volume relations: a broader view. Circulation 1988;77:1203-1212.
28. Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol 2006;290:H1699-H1705.
29. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003;113:717-730.
30. Laplante P, Sirois I, Raymond MA, Kokta V, Beliveau A, Prat A et al. Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis. Cell Death Differ 2010;17:291-303.
31. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-1491.
32. Fan L, Lin C, Zhuo S, Chen L, Liu N, Luo Y et al. Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. Eur J Heart Fail 2009;11:1023-1030.
33. Knauer SK, MannW, Stauber RH. Survivin's dual role: an export's view. Cell Cycle 2007;6: 518-521.
34. Stauber RH, MannW, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007;67:5999-6002.
35. Khan S, Aspe JR, AsumenMG, Almaguel F, Odumosu O, Acevedo-Martinez S et al. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer 2009;100:1073-1086.
36. Mera S, Magnusson M, Tarkowski A, Bokarewa M. Extracellular survivin up-regulates adhesion molecules on the surface of leukocytes changing their reactivity pattern. J Leukoc Biol 2008;83:149-155.
37. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010;121:276-292.
38. Fujii H, Matkar P, Liao C, Rudenko D, Lee PJ, Kuliszewski MA et al. Optimization of ultrasound-mediated anti-angiogenic cancer gene therapy. Mol Ther Nucleic Acids 2013; 2:e94.
39. Bekeredjian R, Chen S, Frenkel PA, Grayburn PA, Shohet RV. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation 2003;108:1022-1026.